Trial Profile
Phase I Study of Lenalidomide to Augment Anti-Tumor Immunity Following Allogeneic Transplantation
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Lymphoma; Multiple myeloma
- Focus Adverse reactions
- 16 Jan 2013 New trial record